AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
All Articles
Multiple Myeloma and Plasma Cell Disorders in 2026: Earlier Bispecifics and a New Amyloidosis Target
By Laahn Foster, MD
The data presented at ASCO 2026 provide more clarity on where bispecifics fit in the treatment sequence, how long to use them, and whether they can be used as an earlier intervention.
Multiple Myeloma and Plasma Cell Disorders in 2026: Earlier Bispecifics and a New Amyloidosis Target
By Laahn Foster, MD
The data presented at ASCO 2026 provide more clarity on where bispecifics fit in the treatment sequence, how long to use them, and whether they can be used as an earlier intervention.
Multiple Myeloma and Plasma Cell Disorders in 2026: Earlier Bispecifics and a New Amyloidosis Target
By Laahn Foster, MD
The data presented at ASCO 2026 provide more clarity on where bispecifics fit in the treatment sequence, how long to use them, and whether they can be used as an earlier intervention.
Relapsed and Refractory DLBCL in 2026: More Options Than Ever, and Three Questions That Actually Matter
By Timothy Fenske, MD
Four of the five randomized R/R DLBCL trials showing overall survival benefit have come in the last four years. Dr. Timothy Fenske maps the 2026 options and the three questions that actually guide treatment selection.
Relapsed and Refractory DLBCL in 2026: More Options Than Ever, and Three Questions That Actually Matter
By Timothy Fenske, MD
Four of the five randomized R/R DLBCL trials showing overall survival benefit have come in the last four years. Dr. Timothy Fenske maps the 2026 options and the three questions that actually guide treatment selection.
Relapsed and Refractory DLBCL in 2026: More Options Than Ever, and Three Questions That Actually Matter
By Timothy Fenske, MD
Four of the five randomized R/R DLBCL trials showing overall survival benefit have come in the last four years. Dr. Timothy Fenske maps the 2026 options and the three questions that actually guide treatment selection.
Rural Cancer Care and the Dollar Sign on Your Diagnosis
By Ariana Sutherland, MSc
A stage 4 breast cancer patient in Juneau had no local oncologist and spent thousands flying to Seattle for care. Her story puts a human face on rural cancer care's structural failures — and what it would take to fix them.
Rural Cancer Care and the Dollar Sign on Your Diagnosis
By Ariana Sutherland, MSc
A stage 4 breast cancer patient in Juneau had no local oncologist and spent thousands flying to Seattle for care. Her story puts a human face on rural cancer care's structural failures — and what it would take to fix them.
Rural Cancer Care and the Dollar Sign on Your Diagnosis
By Ariana Sutherland, MSc
A stage 4 breast cancer patient in Juneau had no local oncologist and spent thousands flying to Seattle for care. Her story puts a human face on rural cancer care's structural failures — and what it would take to fix them.
Daraxonrasib and the RASolute 302 Trial: A Paradigm Shift in the RAS Targeting Era and Management of Pancreatic Cancer
By Ibrahim Halil Sahin, MD; Dr. Meghana Singh
For the first time, a targeted therapy has doubled overall survival in second-line metastatic pancreatic cancer. Two oncologists break down the RASolute 302 trial and what daraxonrasib means for the field.
Daraxonrasib and the RASolute 302 Trial: A Paradigm Shift in the RAS Targeting Era and Management of Pancreatic Cancer
By Ibrahim Halil Sahin, MD; Dr. Meghana Singh
For the first time, a targeted therapy has doubled overall survival in second-line metastatic pancreatic cancer. Two oncologists break down the RASolute 302 trial and what daraxonrasib means for the field.
Daraxonrasib and the RASolute 302 Trial: A Paradigm Shift in the RAS Targeting Era and Management of Pancreatic Cancer
By Ibrahim Halil Sahin, MD; Dr. Meghana Singh
For the first time, a targeted therapy has doubled overall survival in second-line metastatic pancreatic cancer. Two oncologists break down the RASolute 302 trial and what daraxonrasib means for the field.
ASCO 2026: Sima Ehsani Chimeh, MD, on the VIKTORIA-1 Trial in HR+/HER2-Negative Advanced Breast Cancer
By The Cancer News Team
VIKTORIA-1 data show gedatolisib roughly doubled PFS versus alpelisib in PIK3CA-mutant HR+/HER2-negative advanced breast cancer — with a more favorable tolerability profile. An expert breaks down the findings.
ASCO 2026: Sima Ehsani Chimeh, MD, on the VIKTORIA-1 Trial in HR+/HER2-Negative Advanced Breast Cancer
By The Cancer News Team
VIKTORIA-1 data show gedatolisib roughly doubled PFS versus alpelisib in PIK3CA-mutant HR+/HER2-negative advanced breast cancer — with a more favorable tolerability profile. An expert breaks down the findings.
ASCO 2026: Sima Ehsani Chimeh, MD, on the VIKTORIA-1 Trial in HR+/HER2-Negative Advanced Breast Cancer
By The Cancer News Team
VIKTORIA-1 data show gedatolisib roughly doubled PFS versus alpelisib in PIK3CA-mutant HR+/HER2-negative advanced breast cancer — with a more favorable tolerability profile. An expert breaks down the findings.
CAR-T's Real Toxicity Is Delay
By Carolina Escobar, MD
CAR-T physician training centers on managing key toxicities: CRS (fever, hypotension, organ dysfunction) and ICANS (confusion, tremors, seizures).
CAR-T's Real Toxicity Is Delay
By Carolina Escobar, MD
CAR-T physician training centers on managing key toxicities: CRS (fever, hypotension, organ dysfunction) and ICANS (confusion, tremors, seizures).
CAR-T's Real Toxicity Is Delay
By Carolina Escobar, MD
CAR-T physician training centers on managing key toxicities: CRS (fever, hypotension, organ dysfunction) and ICANS (confusion, tremors, seizures).
Bispecific Antibodies and Fixed-Duration CLL Therapy: The Lymphoma and CLL Landscape in 2026
By Jennifer Huang, PhD, MD
The 2026 lymphoma and CLL landscape is defined by maturing long-term data, the shift of bispecific antibodies into earlier treatment lines, and the emergence of all-oral, fixed-duration regimens.
Bispecific Antibodies and Fixed-Duration CLL Therapy: The Lymphoma and CLL Landscape in 2026
By Jennifer Huang, PhD, MD
The 2026 lymphoma and CLL landscape is defined by maturing long-term data, the shift of bispecific antibodies into earlier treatment lines, and the emergence of all-oral, fixed-duration regimens.
Bispecific Antibodies and Fixed-Duration CLL Therapy: The Lymphoma and CLL Landscape in 2026
By Jennifer Huang, PhD, MD
The 2026 lymphoma and CLL landscape is defined by maturing long-term data, the shift of bispecific antibodies into earlier treatment lines, and the emergence of all-oral, fixed-duration regimens.
Early-Stage Lung Cancer in 2026: Why Detection Still Changes Everything
By Thomas Templin, MD MBA
Lung cancer remains the world’s leading cause of cancer death. Reducing tobacco use has helped, but it has not solved the problem.
Early-Stage Lung Cancer in 2026: Why Detection Still Changes Everything
By Thomas Templin, MD MBA
Lung cancer remains the world’s leading cause of cancer death. Reducing tobacco use has helped, but it has not solved the problem.
Early-Stage Lung Cancer in 2026: Why Detection Still Changes Everything
By Thomas Templin, MD MBA
Lung cancer remains the world’s leading cause of cancer death. Reducing tobacco use has helped, but it has not solved the problem.
Why a Child's Zip Code May Be Their Most Important Cancer Prognostic Factor
By The Cancer News Team
To illustrate what a 20% survival rate looks like in practice, Force opens with a case: a 10-year-old boy brought to a rural East African hospital by his grandmother with a progressive jaw mass, intermittent fevers, and microcytic anemia.
Why a Child's Zip Code May Be Their Most Important Cancer Prognostic Factor
By The Cancer News Team
To illustrate what a 20% survival rate looks like in practice, Force opens with a case: a 10-year-old boy brought to a rural East African hospital by his grandmother with a progressive jaw mass, intermittent fevers, and microcytic anemia.
Why a Child's Zip Code May Be Their Most Important Cancer Prognostic Factor
By The Cancer News Team
To illustrate what a 20% survival rate looks like in practice, Force opens with a case: a 10-year-old boy brought to a rural East African hospital by his grandmother with a progressive jaw mass, intermittent fevers, and microcytic anemia.
ASCO 2026: Expert Commentary on the SUCCESSOR-2 Trial in Relapsed/Refractory Multiple Myeloma
By The Cancer News Team
SUCCESSOR-2 extended median PFS to 18 months with mezigdomide plus carfilzomib and dexamethasone in relapsed/refractory myeloma. An expert weighs in on what the phase 3 results mean for community practice.
ASCO 2026: Expert Commentary on the SUCCESSOR-2 Trial in Relapsed/Refractory Multiple Myeloma
By The Cancer News Team
SUCCESSOR-2 extended median PFS to 18 months with mezigdomide plus carfilzomib and dexamethasone in relapsed/refractory myeloma. An expert weighs in on what the phase 3 results mean for community practice.
ASCO 2026: Expert Commentary on the SUCCESSOR-2 Trial in Relapsed/Refractory Multiple Myeloma
By The Cancer News Team
SUCCESSOR-2 extended median PFS to 18 months with mezigdomide plus carfilzomib and dexamethasone in relapsed/refractory myeloma. An expert weighs in on what the phase 3 results mean for community practice.